Healthcentral.Com

04/29/2026 | Press release | Archived content

New Study Sheds Light on Potential for Myelin Repair

Jump To

Myelin is a fatty substance that insulates nerve fibers in the spinal cord and brain. In multiple sclerosis (MS), the immune system mistakenly attacks this coating-a process known as demyelination-leading to disrupted nerve signal transmission. That prompts characteristic MS symptoms like muscle weakness, numbness, bladder control problems, and other issues.

Slowing down the demyelination process is a major focus for MS management, but a new study published in Science suggests there might be an even more exciting option in the future: myelin repair.

Watch More Like This on Drops

Hear what life with a health condition actually looks like. Now in one app. Built for people living with chronic and rare conditions.

In experiments with mice, researchers looked at a type of cell called oligodendrocytes, which the body uses to make myelin sheaths, according to the study's lead author, Dwight Bergles, Ph.D., who runs a research laboratory at the Johns Hopkins University School of Medicine in Baltimore, MD and is a professor in the department of neuroscience. The development of these cells is affected by production of what's called oligodendrocyte precursor cells, or OCPs, and particularly by how they differentiate-which means how much they become specialized toward producing myelin.

"The rate at which OCPs differentiate was remarkably consistent throughout the brain in our research, and that wasn't affected by demyelination," says Bergles. "They are capable of self-renewal. That suggests that myelin repair is merely an extension of this developmental process."

In other words, looking more closely at how OCPs do their work could lead to treatments that boost myelin production, which Bergles says may have a considerable effect on myelin-damaging diseases like MS.

Research Results

Transformation in the Brain

To understand how oligodendrocyte formation happens, the research team assessed how OPCs start their transformation in different mammals, including mice, marmosets, and humans, by using mammalian gene databases that include common molecular markers. With that, they were able to track OPC differentiation in various brain regions.

The next step was looking at this process in the brains of mice, using imaging tools that showed how OPCs differentiate. "This showed us that OPC differentiation was constantly happening all over the brain," says Bergles. "That means there's a possibility to make new oligodendrocytes and myelin anywhere in the brain."

In the last part of the experiment, researchers stripped away new oligodendrocytes and myelin in mouse brains to mimic a disease like MS. They found that OPCs keep going with their differentiation process, but that it can be affected by inflammation.

"This research provides several new insights into the process of myelin formation in the brain," notes Bergles. "This understanding gives us a new way to study where and when this happens in the brain, a question that was not possible to answer before."

Looking Ahead

The Quest to Restore Myelin

Although turning this research into a therapeutic option may be years or even decades away, Bergles suggests that it's a move in the right direction when it comes to MS management.

"These studies highlight areas that may be helpful to investigate for therapeutic targets," he says. "If we can understand the timing of OPC differentiation, we may be able to accelerate the production of new oligodendrocytes and speed functional recovery. But simply forcing more OPCs to differentiate may not be sufficient to enhance myelin repair. That's where more research needs to be done, to find new ways to restore normal myelin."

The recent study results are just part of what's driving optimism for better ways to diagnose and treat MS, says Benjamin Segal, M.D., a neurologist and MS specialist at The Ohio State University Wexner Medical Center in Columbus. Although he wasn't part of the newest research, he notes that results like these are key for a larger effort toward refining and improving the way MS is managed.

"There has been promising research into addressing how myelin is affected by inflammation, and finding ways to stop specific immune cells from attacking myelin, which could then affect MS progression," he says.

For example, he says one of the top directions for disease-modifying treatment is Bruton's tyrosine kinase (BTK) inhibitors, which have been studied in large clinical trials for their ability to slow myelin damage. The next step is what's reflected in the new research, which is restoring myelin, Dr. Segal adds. "We're not at the point where we can do that yet, but research is suggesting we're moving toward that goal, and there's a focused effort on getting toward that goal."

In addition to the recent research, previous studies have looked at using metformin-a medication commonly used for diabetes management-to regenerate myelin. A study in Cell Stem Cell found that the drug showed myelin regrowth in rats by affecting OPCs, for example.

Although myelin repair would be significant for MS treatment, it can also be a potential avenue for other conditions, says Dr. Segal. There are other diseases that involve demyelination, including Guillain-Barré syndrome and Charcot-Marie-Tooth disease, and there may be an effect on Parkinson's disease and Alzheimer's, as well.

"If we can better understand the processes affecting demyelination, we may be able to control the rate of damage, and accelerate the production of new oligodendrocytes," says Bergles. "These findings have important implications for MS and other diseases where myelin loss is significant."

This article was originally published March 16, 2026 and most recently updated April 29, 2026.
© 2026 HealthCentral LLC. All rights reserved.
Sources

Myelin: National Institute of Neurological Disorders and Stroke. (n.d.) "Multiple Sclerosis." https://www.ninds.nih.gov/health-information/disorders/multiple-sclerosis-ms

Main Study: Science. (2026.) "Myelin is repaired by constitutive differentiation of oligodendrocyte progenitors." https://www.science.org/doi/10.1126/science.adu2896

Study Background: Johns Hopkins Medicine. (2026.) "Progenitor Cells in the Brain Constantly Attempt to Produce New Myelin-Producing brain Cells." https://www.hopkinsmedicine.org/news/newsroom/news-releases/2026/01/progenitor-cells-in-the-brain-constantly-attempt-to-produce-new-myelin-producing-brain-cells

Oligodendrocytes: National Ataxia Foundation. (n.d.) "Snapshot: What Are Oligodendrocytes?" https://www.ataxia.org/scasourceposts/snapshot-what-are-oligodendrocytes/

BTK Inhibitors and MS: Therapeutic Advances in Neurological Disorders. (2024.) "A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis." https://pmc.ncbi.nlm.nih.gov/articles/PMC11025433/

Metformin: Cell Stem Cell. (2019.) "Metformin Restores CNS Remyelination Capacity by Rejuvenating Aged Stem Cells." https://pmc.ncbi.nlm.nih.gov/articles/PMC6863391/

Healthcentral.Com published this content on April 29, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 17, 2026 at 11:07 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]